CompanyCRBPNasdaqNorwood, MA

Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals develops antibody drug conjugates and CB1 inverse agonists for oncology and obesity.

SEC EDGAR ClinicalTrials.gov corbuspharma.com

SCHEDULE 13GSep 30Latest SEC filing

Aug 7Latest story

August 2026

Corbus Pharmaceuticals files $127.5 million at-the-market stock offering

Aug 7FinancingCorbus Pharmaceuticals Holdings, Inc.

Corbus reports Q2 2026 results, clears FDA hurdle for CRB-701 trial

Aug 6Quarterly updateCorbus Pharmaceuticals Holdings, Inc.

July 2026

Corbus Pharmaceuticals names Leonardo Viana Nicacio as chief medical officer

Jul 6PeopleCorbus Pharmaceuticals Holdings, Inc.